Key result
Relapsed mediastinal large B-cell lymphoma causes unpaceable complete AV block and fatal cardiogenic shock.
Why the study?
First-line immunochemotherapy cures most patients with primary mediastinal large B-cell lymphoma, but relapse involving the heart carries a guarded prognosis.
Case Report (n=1)
This case highlights the diagnostic difficulties of fibrotic residual mediastinal masses, the poor prognosis of cardiac relapse in primary mediastinal large B-cell lymphoma, and the severe management dilemma of complete atrioventricular block when tumor infiltration precludes cardiac pacing.
Answers are grounded in this paper and cite their sources.
Cardiac relapse in primary mediastinal lymphoma risks unpaceable AV block; Level 5 case leaves open surveillance and management strategies.
Primary mediastinal large B-cell lymphoma (PMBCL) predominantly affects young adults and typically presents as a bulky anterior mediastinal mass. Cure rates with first-line immunochemotherapy are high, but relapse involving the heart carries a guarded prognosis. We describe a woman diagnosed at age 20 with a 15.1 × 14.1 × 14.8 cm anterior mediastinal mass, a 20-kg weight loss, and a lactate dehydrogenase level of 490 U/L. Cervical lymph node biopsy showed diffuse large B-cell lymphoma (CD20- and PAX5-positive, focal CD23- and CD30-, CD15-negative, Ki-67 approximately 40%), which was classified as primary mediastinal. She received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). End-of-treatment PET/CT showed residual uptake above liver uptake (Deauville score 4), which was interpreted at multidisciplinary review as possibly inflammatory, and she was kept under surveillance. Approximately 14 months after treatment, PET/CT showed a maximum standardized uptake value of 25.1 with enlargement of the mass, but surgical biopsy revealed only hyalinized fibrous tissue, with no lymphomatous infiltration on immunohistochemistry. Approximately 26 months after diagnosis, she was admitted with ascites and lower-limb edema. Echocardiography showed a mass infiltrating the right atrium, the right ventricular free wall, and the left atrium, with a mean gradient of 12 mmHg across a narrow right atrioventricular passage. A CT-guided biopsy confirmed PMBCL (Ki-67 approximately 80%); the final report was released after her death. After a prephase with cyclophosphamide, vincristine, and prednisone, she developed complete atrioventricular block (CAVB), attributed to tumor involvement, and no transvenous or epicardial pacing route was feasible. On the 12th day after admission, she developed respiratory failure and cardiorespiratory arrest with return of spontaneous circulation; gemcitabine and oxaliplatin were administered afterwards, and she died the following day of refractory shock, clinically attributed to a cardiogenic mechanism, at age 22. This case report illustrates the limited negative predictive value of biopsy in densely fibrotic residual mediastinal masses, the prognostic relevance of an incomplete metabolic response at the end of first-line therapy, and the therapeutic dilemma of CAVB associated with cardiac lymphoma, where chemotherapeutic cytoreduction is both a potentially reversing therapy and a hemodynamic risk.
No takes yet. Share an insight, caveat, or question.
Neto et al. (2026) conducted a case report in Primary mediastinal large B-cell lymphoma with cardiac infiltration and complete atrioventricular block (n=1). R-CHOP (first-line) followed by CVP prephase and gemcitabine/oxaliplatin at relapse was evaluated. Relapsed primary mediastinal large B-cell lymphoma with cardiac infiltration 26 months post-diagnosis caused unpaceable complete AV block and fatal cardiogenic shock at age 22.
Synapse has enriched 10 related papers. Consider them for comparative context: